UroGen Pharma (URGN) Current Assets (2016 - 2026)

UroGen Pharma (URGN) has reported Current Assets for 11 consecutive years, with $237.5 million the latest figure, recorded in Q1 2026.

• Quarterly Current Assets changed 0.12% year-over-year to $237.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237.5 million (changed 0.12% YoY) and the FY2025 annual result came in at $186.0 million, down 32.63% from the prior year.
• Current Assets advanced to $237.5 million in Q1 2026 per URGN's latest filing, from $186.0 million in the prior quarter.
• Over the last five years, Current Assets for URGN reached as high as $295.1 million in Q3 2024 and fell as low as $81.3 million in Q2 2023.
• A 5-year average of $185.4 million and a median of $182.1 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets soared 242.99% — and 2025, when it sank 42.88%.
• Year by year, Current Assets stood at $128.9 million in 2022, then soared by 31.25% to $169.2 million in 2023, then jumped by 63.21% to $276.1 million in 2024, then slumped by 32.63% to $186.0 million in 2025, then climbed by 27.65% to $237.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $237.5 million, $186.0 million, and $168.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.